Foghorn Therapeutics to Present at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data at Hanson Wade’s 5th Annual Targeted Protein Degradation Summit. The Summit will be held in Danvers, Mass., on October 25–28, 2022. Foghorn is advancing its protein degradation platform and pipeline which includes FHD-609, a first-in-class, highly potent, and selective degrader of BRD9, for the treatment of synovial sarcoma and SMARCB1-loss tumors, and additional programs.
Related news for (FHTX)
- Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
- Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
- Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
- Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025